- Home
- KLRS vs CPHC Comparison
KLRS vs CPHC Comparison
Compare KLRS & CPHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KLRS | CPHC |
|---|---|---|
| Founded | 2019 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 92.8M | 82.1M |
| IPO Year | 2020 | 2016 |
Fundamental Metrics
Financial Performance| Metric | KLRS | CPHC |
|---|---|---|
| Price | $2.93 | $15.78 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $19.00 | N/A |
| AVG Volume (30 Days) | ★ 52.1K | 1.4K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.79% |
| EPS Growth | ★ 75.70 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $165,000.00 | ★ $59,227,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $523.00 |
| Revenue Growth | N/A | ★ 0.14 |
| 52 Week Low | $3.02 | $14.49 |
| 52 Week High | $11.88 | $17.40 |
Technical Indicators
Market Signals| Indicator | KLRS | CPHC |
|---|---|---|
| Relative Strength Index (RSI) | 25.18 | 50.72 |
| Support Level | N/A | $15.13 |
| Resistance Level | $4.37 | $16.03 |
| Average True Range (ATR) | 0.19 | 0.24 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 3.03 | 77.42 |
Price Performance
Historical ComparisonAbout KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About CPHC Canterbury Park Holding Corporation 'New'
Canterbury Park Holding Corp is in the business of pari-mutuel wagering on horse races and unbanked card games at its canterbury park racetrack and card casino facility in Minnesota. The company has four operating segments. The horse racing segment represents pari-mutuel wagering operations on simulcast and lives horse races; the Casino segment represents unbanked card operations; the food and beverage segment includes concessions, catering, and events services provided at the Racetrack; and the real estate development segment represents its real estate development operations. The firm generates a majority of its revenue from the Casino segment.